Table 4.
No of person years | No of cancer events | Adjusted relative risk (95% CI)* | |
---|---|---|---|
Never use | 8 150 250 | 771 | 1.00 |
Ever use (any hormonal contraception) | 7 183 430 | 293 | 0.73 (0.63 to 0.84) |
Former use (any hormonal) | 2 590 322 | 164 | 0.85 (0.71 to 1.02) |
Current or recent use (any hormonal) | 4 593 109 | 129 | 0.61 (0.50 to 0.74) |
Current or recent use (combined OC) | 4 316 888 | 103 | 0.56 (0.45 to 0.70) |
Current or recent use (progestogen only) | 276 221 | 26 | 0.87 (0.59 to 1.29) |
Current or recent use of combined hormonal contraception—oral | |||
Norethisterone, 50 µg ethinylestradiol | 36 494 | 4 | 1.35 (0.50 to 3.61) |
Levonorgestrel, 50 µg ethinylestradiol | 47 335 | 6 | 1.21 (0.54 to 2.71) |
Norethisterone, 30-35 µg ethinylestradiol | 116 090 | 7 | 1.30 (0.62 to 2.76) |
Levonorgestrel, 30-35 µg ethinylestradiol | 519 113 | 11 | 0.33 (0.18 to 0.61) |
Desogestrel, 20-30 µg ethinylestradiol | 988 952 | 17 | 0.45 (0.27 to 0.73) |
Gestodene, 20-35 µg ethinylestradiol | 1 887 047 | 42 | 0.57 (0.41 to 0.79) |
Drospirenone, 20-35 µg ethinylestradiol | 188 928 | 5 | 1.08 (0.44 to 2.64) |
Norgestimate, 35 µg ethinylestradiol | 375 778 | 11 | 0.75 (0.41 to 1.37) |
Cyproterone, 30 µg ethinylestradiol | 142 147 | 0 | — |
Estradiol valerate, dienogest | 1022 | 0 | — |
Current or recent use of combined hormonal contraception—non-oral | |||
Patch | 2253 | 0 | — |
Vaginal ring | 11 729 | 0 | — |
Current or recent use of progestogen-only contraception—oral | |||
Norethisterone | 66 934 | 4 | 0.62 (0.23 to 1.64) |
Levonorgestrel | 6972 | 1 | 1.16 (0.16 to 8.23) |
Desogestrel | 12 155 | 0 | — |
Current or recent use of progestogen-only contraception—non-oral | |||
MPA depot | 7321 | 3 | 6.56 (2.11 to 20.40) |
Implant | 10 575 | 0 | — |
LNG-IUS | 172 265 | 18 | 0.84 (0.53 to 1.35) |
LNG-IUS=levonorgestrel intrauterine system; MPA=medroxyprogesterone acetate.
Adjusted for calendar year, parity, age, education, tubal sterilisation, hysterectomy, endometriosis, polycystic ovary syndrome, and family history of breast or ovarian cancer.